STO Fellows’ Forum (STOFF) 

 

Society for Translational Oncology Fellows' Forum (STOFF) is an intensive 3-day workshop that brings together fellows and junior faculty within 5 years of training completion from the leading medical, surgical, radiation, and pediatric oncology groups and subspecialty fellowships to educate these rising stars on issues around and barriers to successful translational cancer research. A distinguished faculty of prominent scientists, clinicians, ethicists, industry representatives, and biotech investors serve as mentors.

The cornerstone of STOFF is the faculty members who volunteer both their time and wealth of experience. Co-chaired by Stacey Berg (Baylor College of Medicine), Keith Flaherty (Massachusetts General Hospital/Harvard Medical School), and Ross Levine (Memorial Sloan Kettering Cancer Center), the STOFF faculty includes researchers and educators from the US FDA and several leading US cancer centers.

The workshop has received international acclaim for its focused, practical, and personal approach, including opportunities for networking with peers and mentoring from faculty. The broad-based curriculum covers a range of topics related to new drug development. Faculty lecture and lead discussions on preclinical and clinical evaluation, validation of targets and biomarkers, confirmation of mechanism of action and resistance in clinical trials, and racial and age-related disparities in clinical trials, and includes the mechanics of grant-writing and guidelines for good basic research.
 

Educating young oncologists in the field of clinical and translational research is an investment in the future and is likely to impact the quality of cancer patient care for years to come,” said Bruce A. Chabner (Massachusetts General Hospital/Harvard Medical School), who founded the course more than two decades ago. Since then, many of the 540+ alumni have earned significant acclaim in their careers and drug development success.
 

STOFF 2020 Agenda

 

Thursday, January 30, 2020
4:00 PM - 6:00 PM Guest Check-In and Welcome Packets at Registration
6:00 PM - 7:00 PM Welcome Reception
7:00 PM - 7:45 PM Introductions and Keynote Address
Josh Bilenker, MD
7:45 PM - 9:00 PM Dinner
Friday, January 31, 2020
7:00AM - 8:00 AM Breakfast
8:00AM - 8:15 AM Welcome and Course Objectives
Stacey Berg, MD, Keith Flaherty, MD, and Ross Levine, MD
8:15 AM - 9:00 AM Cancer Drug Development: Views from Academia
Bernardo H.L. Goulart, MD, MS
9:00 AM - 9:45 AM Cancer Drug Development: Views from Industry
Peter Hammerman, MD
9:45 AM - 10:00 AM Break
10:00 AM - 10:45 AM The Cost and Value of Cancer Medicine
Thomas Roberts, MD
10:45 AM - 12:15 PM Oncology Drug Development: A Regulatory Perspective
Tatiana Prowell, MD
12:15 PM - 1:30 PM Lunch
  ROUNDTABLE TOPIC 1 - Regulatory Issues
Stacey Berg, MD
  ROUNDTABLE TOPIC 2 - Overcoming Barriers in Career Development and Progression
Ross Levine, MD
  ROUNDTABLE TOPIC 3 - Personalized Cancer Treatment
Bruce A. Chabner, MD
1:30 PM - 2:15 PM Systemic/Toxic Effects
Chloe Villani, PhD
2:15 PM - 3:00 PM Science at the Interface Between the Lab and the Clinic
Ryan Corcoran, MD, PhD
3:15 PM Board Shuttle to the Steven F. Udvar-Hazy Center
3:45 PM - 5:30 PM Visit to the Udvar-Hazy Center
5:30 PM Board Shuttle to return to the Lansdowne
6:30 PM - 8:00 PM Dinner
Saturday, February 1, 2020
7:00AM - 8:00 AM Breakfast
8:00AM - 8:15 AM Welcome and Course Objectives
8:15 AM - 9:00 AM CAR T Cells and Toxicities/Efficacy
Bianca Santomasso, MD
9:00 AM - 9:45 AM Phase 1 Clinical Trials: Protocol Development
Keith Flaherty, MD
9:45 AM - 10:00 AM Break
10:00 AM - 10:45 AM Issues in Design of Translational Research Trials
Susan Hilsenbeck, PhD
10:45 AM - 11:30 AM IRB Issues and PI Responsibilities and Conflict of Interest
Stacey Berg, MD
11:30 AM - 12:15 PM Quantitative and Systems Pharmacology Approach to Personalizing Therapy
Michael Maitland, MD, PhD
12:15 PM - 1:30 PM Lunch
  Mentoring with Co-Chairs - TABLE 1
  Mentoring with Co-Chairs - TABLE 2
  Mentoring with Co-Chairs - TABLE 3
1:30 PM - 2:15 PM Immune Checkpoint Inhibition in Advanced Cancer
Michael Postow, MD
2:15 PM - 3:00 PM Therapeutic resistance including serial biopsy, rapid autopsy and blood-based biomarkers platforms
Dejan Juric, MD
3:00 PM Adjourn

 

STO gratefully acknowledges educational grant support from: